Chul Won Choi
Overview
Explore the profile of Chul Won Choi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
1495
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yoon S, Yoon S, Yang D, Lee G, Sohn S, Shin H, et al.
Int J Cancer
. 2025 Mar;
PMID: 40087986
To prevent thrombosis in patients with polycythemia vera (PV), achieving a complete hematologic response (CHR) is highly recommended in practice. In addition, a reduced JAK2 V617F mutation burden is expected...
2.
Hwang J, Kim H, Kwon J, Yoon S, Jeon M, Yu E, et al.
Blood Cancer J
. 2024 Nov;
14(1):201.
PMID: 39548077
No abstract available.
3.
Jeon M, Yu E, Kim D, Lee B, Lee S, Sung H, et al.
Sci Rep
. 2024 Nov;
14(1):26847.
PMID: 39500976
High-dose melphalan at 200 mg/m (MEL-200) is the standard conditioning regimen before autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM). Busulfan (BU) and cyclophosphamide (CY) can be...
4.
Jeon M, Noh E, Moon S, Yu E, Choi C, Kim D, et al.
Cancer Res Treat
. 2024 May;
56(4):1262-1269.
PMID: 38726507
Purpose: Numerous patients experience long-term complications after hematopoietic stem cell transplantation (HSCT). This study aimed to identify the frequency and risk factors for psychiatric and endocrine complications following HSCT through...
5.
Jeon M, Yu E, Kim D, Choi C, Kim H, Kwon J, et al.
J Clin Lab Anal
. 2024 Mar;
38(6):e25027.
PMID: 38506403
Background: Assessment of bone marrow involvement (BMI) in non-Hodgkin lymphoma (NHL) is crucial for determining patient prognosis and treatment strategy. We assessed the prognostic value of next-generation sequencing (NGS)-based immunoglobulin...
6.
Kim S, Jung J, Ahn S, Kim M, Jeon S, Lee C, et al.
Front Oncol
. 2024 Feb;
14:1307315.
PMID: 38352893
Introduction: Despite the current effective treatments for acute promyelocytic leukemia (APL), early mortality (EM), defined as death within 30 days of presentation, is a major hurdle to long-term survival. Methods:...
7.
Lee S, Hong J, Bang S, Park J, Choi C, Bae S, et al.
J Korean Med Sci
. 2024 Jan;
39(3):e24.
PMID: 38258361
Background: Previous studies have suggested that patients with polycythemia vera (PV) who exhibit hydroxyurea-resistance (HU-R) and -intolerance (HU-I) may have distinct characteristics and clinical outcomes. However, to date, no studies...
8.
Kim J, Jang J, Jo D, Ahn S, Yoon S, Lee J, et al.
J Korean Med Sci
. 2023 Oct;
38(41):e328.
PMID: 37873628
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by uncontrolled terminal complement activation. Eculizumab, a monoclonal antibody C5 inhibitor was introduced in Korea in 2009 and has...
9.
Gill H, Leung G, Ooi M, Teo W, Wong C, Choi C, et al.
Clin Exp Med
. 2023 Sep;
23(8):4199-4217.
PMID: 37747591
Myeloproliferative neoplasms (MPN) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized clinically by the proliferation of one or more hematopoietic lineage(s). The classical Philadelphia-chromosome (Ph)-negative MPNs include...
10.
Kang K, Jeon M, Yu E, Kim D, Lee B, Lee S, et al.
PLoS One
. 2023 Sep;
18(9):e0291268.
PMID: 37703263
Introduction: Pre-emptive therapy for cytomegalovirus (CMV) reactivation has been used in allogeneic hematopoietic stem cell transplantation (allo-HSCT). It is unclear if this strategy has poorer clinical outcomes in CMV-endemic areas...